2155405818ENTRAL FAX CENTER HOWSON AND HOWSON

FED 4 0 2008

		red) U ZUUU		Approved for us	PTO/SB/21 (09-0 e through 07/31/2008. OMB 0651-00:	
Under the Papery	work Reduction Act of 1995	по реглопа	s are required to reapond to a Application Number	collection of in	formation unless.	; U.S. DEPARTMENT OF COMMERC It displays a valid QMB control number	
TRANSMITTAL				10/701,33	10/701,331		
			Filing Date	Novembe	November 4, 2003		
FORM			First Named Inventor	D. Cines	D. Cines		
			Art Unit	1633	1633		
(to be used for all correspondence after initial filing)			Examiner Name	S. Kausha	S. Kaushal		
Total Number of Pages In This Submission 11			Altorney Docket Number	UPN-029	UPN-02908AUSA		
ENCLOSURES (Check all that apply)							
Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/		P P P P C C C C C C C C C C C C C C C C	Drawing(s) Licensing-related Papers Petition Petition Petition to Convert to a Provisional Application Power of Attorney, Revocal Change of Correspondence Ferminal Disclaimer Request for Refund ED, Number of CD(s) Landscape Table on Cts TNo. 00270 Esponse to Office Action metal	a Address	Status Letter Other Enclosure(s) (please Identify below):		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name HO	HOWSON AND HOWSON						
Signature Show E. Bok							
Printed name Mary E. Bak							
Date Feb. 10, 2004 Reg. No. 31,215							
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with							
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature							
NIC /							
Typed or printed name Robert		J. 0.	- Duminiak			Feb. 10, 2006	

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerca. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

FEB 1 0 2006

UPN-O2906AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/701,331

Confirmation No.: 5594

Applicant

: D. Cincs, et al.

Filed

: November 4, 2003

TC/A.U.

: 1633

Examiner

: S. Kaushal

Customer No.

: 00270

Title

: DELIVERY VEHICLE FOR RECOMBINANT PROTEINS

Mail Stop Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF TRANSMISSION OR MAILING UNDER 37 C.F.R. 1.8

I certify that this paper is being facsimile transmitted, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, the United States Patent and Trademark Office, on the

date shown below.

Signed Printed Name

Dated: Fedore 10

RESPONSE UNDER 35 U.S.C. §121 AND AMENDMENT

Sir:

This paper is in timely response to the Office Action dated January 10, 2006.

Please enter the following election and claim amendments.

Election of Species begins on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 9 of this paper.

U.S. Patent Application No. 10/701,331 February 10, 2006 Response to Office Action dated January 10, 2006 Page 2 of 10

ELECTION OF CLAIMS

Applicants hereby elect, without traverse, the claims of Group I, i.e., Claims 9-10, 22 and 33-35, drawn to a recombinant nucleic acid comprising a platelet-specific promoter, a platelet transformed, transduced, infected or transfected thereby, and its therapeutic use. Applicants understand that the election of Group I includes, in part, generic or "linking" claims 1-8, 19-21, and 23-32.

Applicants hereby elect, with traverse, the following species:

megakaryotic/erythrocyte progenitor cells in claim 3;
megakaryocytes in claim 4;
neutrophils in claim 5;
dendritic cells in claim 7;
platelet factor 4 promoter in claim 10;
DEFA1 human neutrophil alpha defensin promoter in claim 12;
human eotaxin gene promoter in claim 16;
megakaryocytes in claim 21; and
u-PA in claim 34.